# Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)

> **NCT01031030** · PHASE3 · UNKNOWN · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 800 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** epirubicin hydrochloride
- **DRUG:** fluorouracil
- **DRUG:** methotrexate
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT01031030
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-11
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01031030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01031030, "Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01031030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*